A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

• Status: Terminated
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Mayo Clinic
• Treatments: Albumin-Bound Paclitaxel; Fluorouracil; Gemcitabine; Leucovorin; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Metastatic pancreatic cancer with metastases amenable to biopsy

• Willingness to provide tissue and blood samples for research purposes

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

Exclusion Criteria:

• History of islet cell, acinar cell, or cystadenocarcinomas

• Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)

• Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry